Filing Flows › Bioventus (BVS) › Q2 2026 › vs Q1 2026
Bioventus (BVS) Q2 2026 vs Q1 2026 (quarter over quarter)
Bioventus's revenue rose $21.1M (+16%) from $132M in Q1 2026 to $153M in Q2 2026. Gross margin 69.0% against 68.7% (+0.3 pts).
Bioventus, Q2 2026: revenue $153M (+4% year over year), operating margin 12.5%, net earnings $33.4M, operating cash flow $19.9M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 69.0% | 68.7% | +0.3 pts |
| Operating margin | 12.5% | 6.4% | +6.1 pts |
| Net margin | 21.8% | 2.4% | +19.5 pts |
| Free cash flow margin | 12.3% | 6.3% | +6.0 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $153M | $132M | $21.1M | +16% |
| Gross profit | $106M | $90.8M | $14.9M | +16% |
| Cost of revenue | $47.5M | $41.3M | $6.2M | +15% |
| Operating profit | $19.1M | $8.4M | $10.7M | +127% |
| Operating expenses | $86.5M | $82.4M | $4.2M | +5% |
| Pre-tax earnings | $15.3M | $4.5M | $10.8M | +239% |
| Other expense, net | $3.8M | $3.9M | −$80K | -2% |
| Research & development | $3.2M | $2.5M | $706K | +29% |
| SG&A | $82.7M | $78.3M | $4.4M | +6% |
| Other operating costs | $626K | $1.6M | −$935K | -60% |
| Income tax benefit | $20.9M | −$571K | $21.5M | — |
| Net earnings | $33.4M | $3.1M | $30.3M | +974% |
| Minority interests | $2.8M | $833K | $1.9M | +232% |
| Depreciation & amortization | $10.9M | $11.2M | −$260K | -2% |
| Share-based compensation | $5.0M | $3.3M | $1.8M | +54% |
| Working capital & other | $29.6M | $8.6M | $20.9M | +242% |
| Operating cash flow | $19.9M | $8.9M | $10.9M | +122% |
| Free cash flow (OCF − capex) | $18.9M | $8.4M | $10.6M | +126% |
| Capital expenditures | $960K | $574K | $386K | +67% |
Questions
How much did Bioventus's revenue grow quarter over quarter in Q2 2026?
Bioventus's revenue rose $21.1M (+16%) from $132M in Q1 2026 to $153M in Q2 2026. Gross margin 69.0% against 68.7% (+0.3 pts).